Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery

Jianjun Cheng, Benjamin A. Teply, Ines Sherifi, Josephine Sung, Gaurav Luther, Frank X. Gu, Etgar Levy-Nissenbaum, Aleksandar F. Radovic-Moreno, Robert Langer, Omid C. Farokhzad

Research output: Contribution to journalArticle

885 Citations (Scopus)

Abstract

Nanoparticle (NP) size has been shown to significantly affect the biodistribution of targeted and non-targeted NPs in an organ specific manner. Herein we have developed NPs from carboxy-terminated poly(d,l-lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-b-PEG-COOH) polymer and studied the effects of altering the following formulation parameters on the size of NPs: (1) polymer concentration, (2) drug loading, (3) water miscibility of solvent, and (4) the ratio of water to solvent. We found that NP mean volumetric size correlates linearly with polymer concentration for NPs between 70 and 250 nm in diameter (linear coefficient=0.99 for NPs formulated with solvents studied). NPs with desirable size, drug loading, and polydispersity were conjugated to the A10 RNA aptamer (Apt) that binds to the prostate specific membrane antigen (PSMA), and NP and NP-Apt biodistribution was evaluated in a LNCaP (PSMA+) xenograft mouse model of prostate cancer. The surface functionalization of NPs with the A10 PSMA Apt significantly enhanced delivery of NPs to tumors vs. equivalent NPs lacking the A10 PSMA Apt (a 3.77-fold increase at 24 h; NP-Apt 0.83%±0.21% vs. NP 0.22%±0.07% of injected dose per gram of tissue; mean±SD, n = 4, p = 0.002). The ability to control NP size together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies.

Original languageEnglish (US)
Pages (from-to)869-876
Number of pages8
JournalBiomaterials
Volume28
Issue number5
DOIs
StatePublished - Feb 1 2007

Fingerprint

Nanoparticles
Polyethylene glycols
Antigens
antineoplaston A10
Pharmaceutical Preparations
Membranes
Polymers
Nucleotide Aptamers
Ethylene Glycol
Water
Polydispersity
Targeted drug delivery
polyethylene glycol-poly(lactide-co-glycolide)
RNA
Heterografts
Tumors
Prostatic Neoplasms
Solubility
Tissue
human glutamate carboxypeptidase II

Keywords

  • Aptamer
  • Drug delivery
  • Nanoparticle
  • PLGA
  • Prostate cancer
  • Targeting

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. / Cheng, Jianjun; Teply, Benjamin A.; Sherifi, Ines; Sung, Josephine; Luther, Gaurav; Gu, Frank X.; Levy-Nissenbaum, Etgar; Radovic-Moreno, Aleksandar F.; Langer, Robert; Farokhzad, Omid C.

In: Biomaterials, Vol. 28, No. 5, 01.02.2007, p. 869-876.

Research output: Contribution to journalArticle

Cheng, J, Teply, BA, Sherifi, I, Sung, J, Luther, G, Gu, FX, Levy-Nissenbaum, E, Radovic-Moreno, AF, Langer, R & Farokhzad, OC 2007, 'Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery', Biomaterials, vol. 28, no. 5, pp. 869-876. https://doi.org/10.1016/j.biomaterials.2006.09.047
Cheng, Jianjun ; Teply, Benjamin A. ; Sherifi, Ines ; Sung, Josephine ; Luther, Gaurav ; Gu, Frank X. ; Levy-Nissenbaum, Etgar ; Radovic-Moreno, Aleksandar F. ; Langer, Robert ; Farokhzad, Omid C. / Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. In: Biomaterials. 2007 ; Vol. 28, No. 5. pp. 869-876.
@article{48a53c2bd3744196bb5d4f33a1cc0205,
title = "Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery",
abstract = "Nanoparticle (NP) size has been shown to significantly affect the biodistribution of targeted and non-targeted NPs in an organ specific manner. Herein we have developed NPs from carboxy-terminated poly(d,l-lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-b-PEG-COOH) polymer and studied the effects of altering the following formulation parameters on the size of NPs: (1) polymer concentration, (2) drug loading, (3) water miscibility of solvent, and (4) the ratio of water to solvent. We found that NP mean volumetric size correlates linearly with polymer concentration for NPs between 70 and 250 nm in diameter (linear coefficient=0.99 for NPs formulated with solvents studied). NPs with desirable size, drug loading, and polydispersity were conjugated to the A10 RNA aptamer (Apt) that binds to the prostate specific membrane antigen (PSMA), and NP and NP-Apt biodistribution was evaluated in a LNCaP (PSMA+) xenograft mouse model of prostate cancer. The surface functionalization of NPs with the A10 PSMA Apt significantly enhanced delivery of NPs to tumors vs. equivalent NPs lacking the A10 PSMA Apt (a 3.77-fold increase at 24 h; NP-Apt 0.83{\%}±0.21{\%} vs. NP 0.22{\%}±0.07{\%} of injected dose per gram of tissue; mean±SD, n = 4, p = 0.002). The ability to control NP size together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies.",
keywords = "Aptamer, Drug delivery, Nanoparticle, PLGA, Prostate cancer, Targeting",
author = "Jianjun Cheng and Teply, {Benjamin A.} and Ines Sherifi and Josephine Sung and Gaurav Luther and Gu, {Frank X.} and Etgar Levy-Nissenbaum and Radovic-Moreno, {Aleksandar F.} and Robert Langer and Farokhzad, {Omid C.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.biomaterials.2006.09.047",
language = "English (US)",
volume = "28",
pages = "869--876",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery

AU - Cheng, Jianjun

AU - Teply, Benjamin A.

AU - Sherifi, Ines

AU - Sung, Josephine

AU - Luther, Gaurav

AU - Gu, Frank X.

AU - Levy-Nissenbaum, Etgar

AU - Radovic-Moreno, Aleksandar F.

AU - Langer, Robert

AU - Farokhzad, Omid C.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Nanoparticle (NP) size has been shown to significantly affect the biodistribution of targeted and non-targeted NPs in an organ specific manner. Herein we have developed NPs from carboxy-terminated poly(d,l-lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-b-PEG-COOH) polymer and studied the effects of altering the following formulation parameters on the size of NPs: (1) polymer concentration, (2) drug loading, (3) water miscibility of solvent, and (4) the ratio of water to solvent. We found that NP mean volumetric size correlates linearly with polymer concentration for NPs between 70 and 250 nm in diameter (linear coefficient=0.99 for NPs formulated with solvents studied). NPs with desirable size, drug loading, and polydispersity were conjugated to the A10 RNA aptamer (Apt) that binds to the prostate specific membrane antigen (PSMA), and NP and NP-Apt biodistribution was evaluated in a LNCaP (PSMA+) xenograft mouse model of prostate cancer. The surface functionalization of NPs with the A10 PSMA Apt significantly enhanced delivery of NPs to tumors vs. equivalent NPs lacking the A10 PSMA Apt (a 3.77-fold increase at 24 h; NP-Apt 0.83%±0.21% vs. NP 0.22%±0.07% of injected dose per gram of tissue; mean±SD, n = 4, p = 0.002). The ability to control NP size together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies.

AB - Nanoparticle (NP) size has been shown to significantly affect the biodistribution of targeted and non-targeted NPs in an organ specific manner. Herein we have developed NPs from carboxy-terminated poly(d,l-lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-b-PEG-COOH) polymer and studied the effects of altering the following formulation parameters on the size of NPs: (1) polymer concentration, (2) drug loading, (3) water miscibility of solvent, and (4) the ratio of water to solvent. We found that NP mean volumetric size correlates linearly with polymer concentration for NPs between 70 and 250 nm in diameter (linear coefficient=0.99 for NPs formulated with solvents studied). NPs with desirable size, drug loading, and polydispersity were conjugated to the A10 RNA aptamer (Apt) that binds to the prostate specific membrane antigen (PSMA), and NP and NP-Apt biodistribution was evaluated in a LNCaP (PSMA+) xenograft mouse model of prostate cancer. The surface functionalization of NPs with the A10 PSMA Apt significantly enhanced delivery of NPs to tumors vs. equivalent NPs lacking the A10 PSMA Apt (a 3.77-fold increase at 24 h; NP-Apt 0.83%±0.21% vs. NP 0.22%±0.07% of injected dose per gram of tissue; mean±SD, n = 4, p = 0.002). The ability to control NP size together with targeted delivery may result in favorable biodistribution and development of clinically relevant targeted therapies.

KW - Aptamer

KW - Drug delivery

KW - Nanoparticle

KW - PLGA

KW - Prostate cancer

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=33750503424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750503424&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2006.09.047

DO - 10.1016/j.biomaterials.2006.09.047

M3 - Article

C2 - 17055572

AN - SCOPUS:33750503424

VL - 28

SP - 869

EP - 876

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 5

ER -